SUPRENZA Drug Patent Profile
✉ Email this page to a colleague
When do Suprenza patents expire, and what generic alternatives are available?
Suprenza is a drug marketed by Citius Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has two patent family members in two countries.
The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Suprenza
A generic version of SUPRENZA was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUPRENZA?
- What are the global sales for SUPRENZA?
- What is Average Wholesale Price for SUPRENZA?
Summary for SUPRENZA
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 44 |
| Patent Applications: | 909 |
| Drug Prices: | Drug price information for SUPRENZA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SUPRENZA |
| DailyMed Link: | SUPRENZA at DailyMed |
Paragraph IV (Patent) Challenges for SUPRENZA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SUPRENZA | Orally Disintegrating Tablets | phentermine hydrochloride | 37.5 mg | 202088 | 1 | 2013-03-22 |
| SUPRENZA | Orally Disintegrating Tablets | phentermine hydrochloride | 15 mg and 30 mg | 202088 | 1 | 2012-10-19 |
US Patents and Regulatory Information for SUPRENZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUPRENZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUPRENZA
See the table below for patents covering SUPRENZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 1001748 | ⤷ Sign Up | |
| Japan | 4947833 | ⤷ Sign Up | |
| European Patent Office | 2254558 | COMPRIMÉS À DISSOLUTION ORALE AYANT UN ASPECT MOUCHETÉ (ORALLY DISINTEGRATING TABLETS WITH SPECKLED APPEARANCE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SUPRENZA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2317997 | 2190050-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
